Redefining trial access
10th February 2026 Uncategorised 0Re:Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials More: Redefining trial access Source: News
read more
Re:Cognition Health and Cera collaborate to expand access to Alzheimer’s and neurodegenerative clinical trials More: Redefining trial access Source: News
read moreNovo’s star-studded Wegovy pill promotion earned the top spot among the pharma ads that played during the Super Bowl, according to TV outcomes company EDO’s ranking of the ads that earned the most engagement. More: Pharma's 2026 Super Bowl ads:
read moreNovartis CEO Vas Narasimhan saw his realized compensation swell by 30% in 2025, reaching 24.9 million Swiss francs ($32.4M) as the Swiss pharma giant exceeded its long-term financial and innovation targets. More: Novartis CEO pay soars 30% to M following
read moreA new campaign from Otsuka aims to educate healthcare professionals about the far-reaching impacts of attention-deficit/hyperactivity disorder on patients’ lives, beyond just the diagnostic symptoms of the condition. More: Otsuka awareness campaign urges HCPs to see ‘All of ADHD’ Source:
read moreBristol Myers Squibb has signed an agreement to partner with Evinova’s AI-native clinical development platform across the company’s global portfolio in an effort to improve efficiency and cut costs. More: Bristol Myers and Evinova pen global development partnership Source: fierce
read moreThe agreement will see Phlow as the first drugmaker to produce epinephrine injection API in the U.S., while Fresenius will work on formulation and finished doses to ship to U.S. hospitals and clinics, the companies said. More: Fresenius Kabi, Phlow
read more© 1994 - 2026 B.M. Pharmaceuticals